Dashboard
1
Poor Management Efficiency with a low ROCE of 38.04%
- The company has been able to generate a Return on Capital Employed (avg) of 38.04% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 13.76% and Operating profit at 13.35% over the last 5 years
4
Negative results in Jun 26
5
With ROE of 23.82%, it has a fair valuation with a 2.94 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 12,593 Million (Large Cap)
12.00
NA
4.50%
-0.66
23.50%
3.22
Revenue and Profits:
Net Sales:
831 Million
(Quarterly Results - Jun 2026)
Net Profit:
288 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.91%
0%
-3.91%
6 Months
-14.14%
0%
-14.14%
1 Year
-28.74%
0%
-28.74%
2 Years
14.31%
0%
14.31%
3 Years
-27.39%
0%
-27.39%
4 Years
12.83%
0%
12.83%
5 Years
-23.76%
0%
-23.76%
Tibet Rhodiola Pharmaceutical Holding Co. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.76%
EBIT Growth (5y)
13.35%
EBIT to Interest (avg)
63.21
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.64
Sales to Capital Employed (avg)
0.63
Tax Ratio
11.64%
Dividend Payout Ratio
60.38%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
42.79%
ROE (avg)
17.58%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
2.94
EV to EBIT
9.86
EV to EBITDA
9.23
EV to Capital Employed
7.66
EV to Sales
2.91
PEG Ratio
NA
Dividend Yield
4.94%
ROCE (Latest)
77.65%
ROE (Latest)
23.82%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
830.90
723.50
14.84%
Operating Profit (PBDIT) excl Other Income
265.20
236.70
12.04%
Interest
12.20
10.10
20.79%
Exceptional Items
-3.00
-2.10
-42.86%
Consolidate Net Profit
288.30
282.80
1.94%
Operating Profit Margin (Excl OI)
290.90%
294.70%
-0.38%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 14.84% vs -18.92% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 1.94% vs 47.99% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,950.60
2,776.30
6.28%
Operating Profit (PBDIT) excl Other Income
1,003.40
967.90
3.67%
Interest
12.80
9.60
33.33%
Exceptional Items
-3.50
-18.80
81.38%
Consolidate Net Profit
917.00
1,057.10
-13.25%
Operating Profit Margin (Excl OI)
313.40%
321.90%
-0.85%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 6.28% vs -10.52% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -13.25% vs 30.47% in Dec 2024
About Tibet Rhodiola Pharmaceutical Holding Co. 
Tibet Rhodiola Pharmaceutical Holding Co.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






